Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.


Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents include monoclonal antibodies, tyrosine-kinase inhibitors, and peptibodies. Many of these agents, including bevacizumab, pazopanib, nintedanib, cediranib, and trebananib, have been evaluated in randomized Phase III clinical trials, and all have demonstrated a progression-free survival (PFS) benefit. Specifically, maintenance pazopanib was shown to improve PFS in women with newly diagnosed EOC. Pazopanib, an oral TKI, inhibits several kinase receptors, including those for vascular endothelial growth factor (-1,-2,-3), platelet-derived growth factor (-α and -β), and fibroblast growth factor. It also targets stem cell-factor receptor (c-kit), interleukin 2-inducible T-cell kinase, lymphocyte-specific protein tyrosine kinase, and colony-stimulating factor 1 receptor. Pazopanib has been investigated in several Phase II and III clinical trials, with results indicating a potential role in the management of EOC. This article provides an overview of pazopanib in the treatment of EOC.





Published Version (Please cite this version)


Publication Info

Davidson, Brittany A, and Angeles Alvarez Secord (2014). Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Womens Health, 6. pp. 289–300. 10.2147/IJWH.S49781 Retrieved from

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Brittany A Davidson

Associate Professor of Obstetrics and Gynecology

My research passion lies at the intersection of gynecologic cancers and palliative care, helping patients with GYN cancers and their families navigate the journey of their cancer diagnoses to maximize their quality of life and mitigate aggressive and futile care near the end of life. I am also passionate about how the healthcare team communicates with patients and their families. Cancer care should be patient-centered based on an individual's own values--this requires comprehensive goals of care conversations early and often throughout the cancer trajectory. This has led me to become involved in VitalTalk Communication Skills training, which I have taught both locally at Duke and across the country to clinicians in various clinical settings. 

Clinically, caring for patients with gestational trophoblastic neoplasms and cancers in adolescents and young adults is a rewarding aspect of my job. Helping patients and their families navigate cancer diagnoses and the potential impact this has on growing families is rewarding. I enjoy working in a multi-disciplinary approach with our reproductive endocrinology, psychology, and cancer support teams to maximize longevity, quality of life and family building opportunities. 

As the program director for the OB/GYN department, medical education and simulation is also near and dear to my heart. I find great joy in mentoring trainees at all stages and in all venues--clinically, research, and professionally.


Angeles Alvarez Secord

Professor of Obstetrics and Gynecology

My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.

In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.